Economic Evaluation of Midazolam–Droperidol Combination, Versus Droperidol or Olanzapine for the Management of Acute Agitation in the Emergency Department: A Within-Trial Analysis

Celene Y. L. Yap (), Ya-seng (Arthur) Hsueh (), Jonathan C. Knott (), David McD Taylor (), Esther W. Chan () and David C. M. Kong ()
Additional contact information
Celene Y. L. Yap: Monash University
Ya-seng (Arthur) Hsueh: The University of Melbourne
Jonathan C. Knott: Royal Melbourne Hospital
David McD Taylor: Austin Health
Esther W. Chan: The University of Hong Kong
David C. M. Kong: Monash University

PharmacoEconomics - Open, 2018, vol. 2, issue 2, No 6, 151 pages

Abstract: Abstract Background The combination of midazolam and droperidol has proven superior to droperidol or olanzapine monotherapy in the management of acute agitation in emergency departments (EDs). Objective This is the first economic analysis to evaluate the cost–benefit and cost effectiveness of the midazolam–droperidol combination compared with droperidol or olanzapine for the management of acute agitation in EDs. Methods This analysis used data derived from a randomised, controlled, double-blind clinical trial conducted in two metropolitan Australian EDs between October 2014 and August 2015. The economic evaluation was from the perspective of Australian public hospital EDs. The main outcomes included agitation management time and the agitation-free time gained. Sensitivity analyses were undertaken. Results The midazolam–droperidol combination was the least costly regimen (Australian dollars [AU$]46.25 per patient) compared with the droperidol and olanzapine groups (AU$92.18 and AU$110.45 per patient, respectively). The main cost driver for all groups was the cost of the labour required during the initial adequate sedation. The combination afforded an additional 10–13 min of mean agitation-free time gained, which can be translated to additional savings of AU$31.24–42.60 per patient compared with the droperidol and olanzapine groups. The benefit–cost ratio for the midazolam–droperidol combination was 12.2:1.0, or AU$122,000 in total benefit for every AU$10,000 spent on management of acute agitation. Sensitivity analyses over key variables indicated these results were robust. Conclusions The midazolam–droperidol combination may be a cost-saving and dominant cost-effective regimen for the treatment of acute agitation in EDs as it is more effective and less costly than either droperidol or olanzapine monotherapy.

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-017-0047-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0047-y

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-017-0047-y

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().